Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.
Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: Lillian Bitner Clear advanced filters

  • A proof-of-concept clinical trial of patients with histiocytoses with MAPK-pathway mutations showed durable responses to treatment with the MEK1 and MEK2 inhibitor cobimetinib, which indicates that histiocytic neoplasms are dependent on MAPK signalling.

    • Eli L. Diamond
    • Benjamin H. Durham
    • David M. Hyman
    Research
    Nature
    Volume: 567, P: 521-524

  • A range of SF3B1 mutations promote tumorigenesis through the repression of BRD9, a core component of the non-canonical BAF complex, and correcting BRD9 mis-splicing in these SF3B1-mutant cells suppresses tumour growth.

    • Daichi Inoue
    • Guo-Liang Chew
    • Robert K. Bradley
    Research
    Nature
    Volume: 574, P: 432-436